`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTICT OF DELAWARE
`
`AMARIN PHARMA, INC., AMARIN
`PHARMACEUTICALS IRELAND
`LilvIITED, MOCHIDA
`PHARMACEUTICAL CO., LTD.,
`
`Plaintiffs,
`
`V.
`
`C.A. No. 20-1630-RGA-JLH
`
`HIKMA PHARMACEUTICALS USA
`INC., HIKMA PHARMACEUTICALS
`PLC, AND HEAL TH NET, LLC
`
`Defendants.
`
`FINAL JUDGMENT UNDER
`FEDERAL RULE OF CIVIL PROCEDURE 54(b)
`
`THIS MATTER having come before the Court on Defendants Hikma Pharmaceuticals
`
`I
`
`USA Inc. and Hikma Pharmaceuticals PLC's (collectively, "Hikma") Motion for Entry of Final
`
`and:Appealable Judgment under Federal Rule of Civil Procedure 54(b), and the Court having
`
`con~idered Hikma's argupients and Sl,!bmissions in 1mpport of the Motion;
`
`It is hereby ORDERED that the Motion is GRANTED.
`
`For the reasons set forth by Hikma in its moving papers, the Court finds that the Court's
`
`ord~r granting Hikma's motion to dismiss Plaintiffs' first amended complaint (D.I. 98) is a final
`
`judgment resolving Plaintiffs' claims against Hikma, and the Court expressly detemiines that there
`
`is no just reason for delay,(see Fed. R. Civ. P. 54(b)).
`
`Considering the factors set forth in Berckeley Inv. Grp., Ltd. v. Colkitt, 455 F.3d 195, 203
`
`(3d Cir. 2006), the Court finds that (1) the relationship between the adjud1eated claims against
`
`Hikma and the unadjudicated claims against the remaining Defendant, Health Net, LLC, is
`
`
`
`Case 1:20-cv-01630-RGA-JLH Document 144 Filed 10/13/22 Page 2 of 2 PageID #: 1990
`
`minimal because Plaintiffs theories of infringement against these respective defendants are
`
`materially different; (2) the only foreseeable possibility that the need for review might be mooted
`
`by future developments in this Court is the invalidation of the asserted patents, which is unlikely
`
`I
`
`to :occur for more than a year; (3) the possibility that the reviewing court might be obliged to
`
`consider the same issue 8: second time is minimal because any appeal of the Court's order granting
`
`Hikma's motion to dismiss does not relate to Plaintiffs' infringement theory against Health Net;
`
`( 4) there is no claim or counterclaim which could result in a set-off against the judgment sought to
`'
`be: made final; and (5) no miscellaneous factors (such as delay, economic and solvency
`
`co~siderations, shortening the time of trial, frivolity of competing claims, expense, and the like)
`
`I
`
`weigh against entering final judgment at this time.
`!
`
`Accordingly, final judgment is ENTERED in favor of Hikma and against Plaintiffs;
`
`Plaintiffs' claims against Hikma in this action are DISMISSED WITH PREJUDICE; and each
`
`I
`
`•
`
`party shall bear its own costs and fees. ~
`
`IT IS SO ORDERED this JJ_ day o f~ , 2022.
`
`United States District Court Judge
`
`2
`
`